Compounds > pravastatin
Page last updated: 2024-08-23

pravastatin and Kahler Disease

pravastatin has been researched along with Kahler Disease in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bohatch-Junior, MS; Favero, GM; Fernandes, D; Krum, EA; Nogaroto, V; Otuki, MF; Souza-Fonseca-Guimarães, F; Svidnicki, PV; Trojan, PJ1
Hildebrandt, GC; Panu, LD; Shahan, JL1
Eto, M; Fujii, T; Hatayama, T; Hyodoh, F; Otsuki, T; Sakaguchi, H; Sugihara, T; Takata, A; Tsujioka, T1
Aoyama, T; Hara, S; Iwata, H; Kami, M; Kanda, Y; Matsuo, K; Mori, S; Murashige, N; Mutou, Y; Odawara, M; Suzuki, R; Tachibana, S; Takeuchi, K; Yamane, M1

Other Studies

4 other study(ies) available for pravastatin and Kahler Disease

ArticleYear
Pravastatin induces cell cycle arrest and decreased production of VEGF and bFGF in multiple myeloma cell line.
    Brazilian journal of biology = Revista brasleira de biologia, 2016, Volume: 76, Issue:1

    Topics: Anticholesteremic Agents; Cell Cycle Checkpoints; Cell Line; Cholesterol; Fibroblast Growth Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multiple Myeloma; Pravastatin; Vascular Endothelial Growth Factor A

2016
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
    International journal of hematology, 2012, Volume: 96, Issue:6

    Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatine Kinase, MM Form; Cyclohexanecarboxylic Acids; Dexamethasone; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunologic Factors; Kidney Diseases; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Pravastatin; Pyrazines; Rhabdomyolysis; Thalidomide

2012
IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor.
    International journal of oncology, 2003, Volume: 23, Issue:3

    Topics: Bromodeoxyuridine; Cell Cycle; Cell Division; Cell Line, Tumor; Coloring Agents; DNA, Complementary; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Multiple Myeloma; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; RNA; Water

2003
Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies.
    Cancer science, 2006, Volume: 97, Issue:2

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Japan; Lymphoma; Male; Multiple Myeloma; Pravastatin; Risk Factors; Simvastatin

2006